drugset / Trial / NCT05647512

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

NCT05647512

Phase 1/2 Withdrawn LaNova Medicines Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Timeline

Start
2023-01-18
Primary completion
2024-12-01
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule Oral
Subject LM-305 Unknown Intravenous

Indications